MedTrace Logo

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

NCT00616733 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-03-10

No results posted yet for this study

Summary

This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.

Conditions

Interventions

DRUG

CS-0777 tablets

0.1 mg, once-weekly, for 12 weeks

DRUG

CS-0777 tablets

0.3 mg, once-weekly or once every 2 weeks, for 12 weeks

DRUG

CS-0777 tablets

0.6 mg, once-weekly or once every 2 weeks, for 12 weeks

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00616733 on ClinicalTrials.gov